Medincell SA said it priced a roughly €48 million private placement of 2.37 million new ordinary shares at €20.35 per share, a 10% discount to the March 5, 2026 close. The unregistered offering, made without preferential subscription rights to qualified or restricted investors, was backed by healthcare specialist investors including Perceptive Advisors, Kurma Growth Opportunities Fund, Affinity Asset Advisors and Polar Capital alongside existing shareholders. Proceeds will support the company’s growth strategy, including expanding partnering opportunities and strengthening its long-acting injectable technology platform, with the new shares expected to begin trading on Euronext Paris on March 10, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medincell SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260305432026) on March 06, 2026, and is solely responsible for the information contained therein.